OncoBayes has developed a single, de-risked molecule — OB-001 — that blocks the key efflux pumps involved in ADC payload resistance, as well as impacting the brain concentration of TKIs.
| Website | http://oncobayes.com |
| Employees | 2 (1 on RocketReach) |
| Industry | Biotechnology Research |
Looking for a particular OncoBayes employee's phone or email?
OncoBayes Questions
Jim Millen is the CEO of OncoBayes.
1 people are employed at OncoBayes.
Top OncoBayes Employees
-
Jim Millen
CEO at OncoBayes
Oxford, GB3
G2Crowd Trusted
300K+
Plugin Users
